{
    "info": {
        "nct_id": "NCT05828511",
        "official_title": "Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma",
        "inclusion_criteria": "1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n2. Confirmed diagnosis of symptomatic multiple myeloma (MM) by International Myeloma Working Group (IMWG) diagnosis criteria\n3. Measurable disease, according to the 2016 IMWG response criteria, as defined in the protocol\n4. No prior therapy for MM, with the exception of prior emergent or palliative radiation and up to 1 month of single-agent corticosteroids, with washout periods as per the protocol\n5. Participants must have evidence of adequate bone marrow reserves and hepatic, renal and cardiac function as defined in the protocol\n6. Participants must be age <70 and have adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible. The specific thresholds for adequate organ function are as per institutional guidance.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Receiving any concurrent investigational agent with known or suspected activity against MM, or agents targeting the A proliferation-inducing ligand (APRIL)/ Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis\n2. Known central nervous system (CNS) involvement with MM, known or suspected progressive multifocal leukoencephalopathy (PML), a history of neurocognitive conditions, or CNS movement disorder, or history of seizure within 12 months prior to study enrollment\n3. Rapidly progressive symptomatic disease, (e.g. progressing renal failure or hypercalcemia not responsive to standard medical interventions), in urgent need of treatment with chemotherapy\n4. Diagnosis of non-secretory MM, active plasma cell leukemia, primary light-chain (AL) amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or known POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)\n\nNote: Other protocol-defined Inclusion/Exclusion criteria apply",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "2. Confirmed diagnosis of symptomatic multiple myeloma (MM) by International Myeloma Working Group (IMWG) diagnosis criteria",
            "criterions": [
                {
                    "exact_snippets": "Confirmed diagnosis of symptomatic multiple myeloma (MM)",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "by International Myeloma Working Group (IMWG) diagnosis criteria",
                    "criterion": "IMWG diagnostic criteria for multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "meets IMWG criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Participants must have evidence of adequate bone marrow reserves and hepatic, renal and cardiac function as defined in the protocol",
            "criterions": [
                {
                    "exact_snippets": "evidence of adequate bone marrow reserves",
                    "criterion": "bone marrow reserves",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... hepatic ... function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... cardiac function",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. No prior therapy for MM, with the exception of prior emergent or palliative radiation and up to 1 month of single-agent corticosteroids, with washout periods as per the protocol",
            "criterions": [
                {
                    "exact_snippets": "No prior therapy for MM",
                    "criterion": "prior therapy for MM",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of prior emergent or palliative radiation",
                    "criterion": "prior emergent or palliative radiation",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "up to 1 month of single-agent corticosteroids",
                    "criterion": "prior single-agent corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with washout periods as per the protocol",
                    "criterion": "washout periods for prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "protocol adherence",
                            "expected_value": "as per the protocol"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Participants must be age <70 and have adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible. The specific thresholds for adequate organ function are as per institutional guidance.",
            "criterions": [
                {
                    "exact_snippets": "age <70",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 70,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible ... The specific thresholds for adequate organ function are as per institutional guidance.",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": "as per institutional guidance"
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible ... The specific thresholds for adequate organ function are as per institutional guidance.",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": "as per institutional guidance"
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible ... The specific thresholds for adequate organ function are as per institutional guidance.",
                    "criterion": "pulmonary function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": "as per institutional guidance"
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible ... The specific thresholds for adequate organ function are as per institutional guidance.",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": "as per institutional guidance"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Measurable disease, according to the 2016 IMWG response criteria, as defined in the protocol",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "according to the 2016 IMWG response criteria, as defined in the protocol",
                    "criterion": "disease measurability assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "2016 IMWG response criteria as defined in the protocol"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "Note: Other protocol-defined Inclusion/Exclusion criteria apply",
            "criterions": [
                {
                    "exact_snippets": "Other protocol-defined Inclusion/Exclusion criteria apply",
                    "criterion": "protocol-defined Inclusion/Exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Receiving any concurrent investigational agent with known or suspected activity against MM, or agents targeting the A proliferation-inducing ligand (APRIL)/ Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis",
            "criterions": [
                {
                    "exact_snippets": "Receiving any concurrent investigational agent with known or suspected activity against MM",
                    "criterion": "concurrent investigational agent with activity against MM",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "agents targeting the A proliferation-inducing ligand (APRIL)/ Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis",
                    "criterion": "agents targeting APRIL/TACI/BCMA axis",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Rapidly progressive symptomatic disease, (e.g. progressing renal failure or hypercalcemia not responsive to standard medical interventions), in urgent need of treatment with chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Rapidly progressive symptomatic disease",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": "rapidly progressive"
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progressing renal failure",
                    "criterion": "renal failure",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypercalcemia not responsive to standard medical interventions",
                    "criterion": "hypercalcemia",
                    "requirements": [
                        {
                            "requirement_type": "responsiveness to standard medical interventions",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "in urgent need of treatment with chemotherapy",
                    "criterion": "need for chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "urgency",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Diagnosis of non-secretory MM, active plasma cell leukemia, primary light-chain (AL) amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or known POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of non-secretory MM",
                    "criterion": "non-secretory multiple myeloma (MM)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... active plasma cell leukemia",
                    "criterion": "active plasma cell leukemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... primary light-chain (AL) amyloidosis",
                    "criterion": "primary light-chain (AL) amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... Waldenström macroglobulinemia (lymphoplasmacytic lymphoma)",
                    "criterion": "Waldenström macroglobulinemia (lymphoplasmacytic lymphoma)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... known POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)",
                    "criterion": "POEMS syndrome",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "2. Known central nervous system (CNS) involvement with MM, known or suspected progressive multifocal leukoencephalopathy (PML), a history of neurocognitive conditions, or CNS movement disorder, or history of seizure within 12 months prior to study enrollment",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}